Project
Amgen Efavaleukin Alfa
Automatically Closed · 2022 until 2023
Eckhold Annika, Krieger-Grübel Claudia, Brand Stephan
Type
Clinical Studies
Range
Multicentric, KSSG as participating partner
Units
Status
Automatically Closed
Start Date
2022
End Date
2023
Financing
Industry
Study Design
Double blinded, 3 arms
Brief description/objective
A Phase 2, Multicenter, Dose-finding, Double blinded, Pla-cebo- Controlled Study to Evaluate the Safety and Effi-cacy of Efavaleukin Alfa Induc-tion Therapy in Patients with Mederatly to Severely UC